Haven't used Regulonix Holding, Inc. yet?
Ask Trustburn

Questions about Regulonix Holding, Inc.

Based on 9 reviews, listing data and website checks · updated yesterday

What is Regulonix Holding, Inc.?

Regulonix Holding, Inc. is an early-stage biotechnology company developing non-opioid drugs for chronic pain. They focus on targeting the sodium channel NaV1.7 to create compounds that are non-addictive and more effective than morphine. Their platform aims to address a global pain management therapeutics market projected to reach $83B by 2024.

What themes do several reviewers share about their experience with Regulonix?

Several reviewers praised the company for having a website that is user-friendly, intuitive, and visually appealing. Customers also noted that the support team is professional, prompt, and always ready to assist with queries.

What is the current rating split and how many reviews exist for this business?

The Trustburn rating for Regulonix is 4.2 out of 5 from 9 reviews. The rating split includes five 5-star reviews, four 4-star reviews, and two 3-star reviews.

How can I contact Regulonix Holding, Inc.?

You can reach Regulonix Holding, Inc. by e-mail at [email protected].

What is the official website of Regulonix Holding, Inc.?

The official website of Regulonix Holding, Inc. is regulonix.com.

Based on reviews, listing data and the company's website. Verify anything important with the company directly.

Jacques Doubell
Reviews 1

I recently used the services of a company. I must say I am extremely satisfied with their services. The website is user-friendly and visually appealing. The support team is professional and prompt in resolving queries. Keep up the good work!

Kevin Cloherty
Reviews 1

Using the services of Regulonix Holding, Inc. has been a delightful experience. The website is easy to use and navigate. Their customer support team is always quick to respond and provides satisfactory solutions. I would highly recommend their services to anyone.

Greg Torbet
Reviews 1

Regulonix Holding, Inc. has exceeded my expectations in terms of services. The website is user-friendly and easy to navigate. The customer support team is always available and attentive to my needs. I am extremely satisfied with their services.

Maria Bozhanova
Reviews 1

I recently availed the services of a company for my business. I must say I am highly impressed with their services. The website is intuitive and visually appealing. The support team is friendly and responsive. I am glad to have chosen them.

Dominique Travel
Reviews 1

I have been a customer of Regulonix Holding, Inc. for several months now and I must say their services have been highly satisfactory. The website is user-friendly and the support team is always available to help. I highly recommend their services.

Courtni Berghoefer
Reviews 1

Regulonix Holding, Inc. is an average company. I had a decent experience with their services. However, there is room for improvement. The website regulonix.com is user-friendly and easy to navigate. The customer support team was prompt in responding to my queries. Overall, I would rate them as average.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="regulonix-com" data-lang="en"></div>
More widgets

About Regulonix Holding, Inc.

Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. By indirectly targeting the sodium channel NaV1.7 – a well-established and genetically validated pain target – and focusing on the signaling pathways that control this channel’s activity, the Regulonix team has isolated compounds demonstrated in animal models to be non-addictive and more effective than morphine. This unique platform helps address a global pain management therapeutics market projected to reach $83B by 2024, affecting more than 100 million Americans and 1.5 billion people globally.